Physician profile
Ruby Parveen
NPI 1457540882
$3,990.31
in general payments reported to CMS, 2019-2025
47 companies · $852 in 2025
The $852 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $572 · 2021: $515 · 2022: $465 · 2023: $645 · 2024: $632 · 2025: $852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,130.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $472.02 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $295.78 | 2020-2025 | Austedo Xr, Austedo Xr |
| Ucb, INC. | $256.42 | 2020-2025 | Rystiggo, Nayzilam, Briviact |
| Inspire Medical Systems, INC. | $229.10 | 2023-2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $198.40 | 2021-2025 | |
| Abbott Laboratories | $191.49 | 2022-2025 | Infinity |
| Argenx US, INC. | $184.23 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Allergan, INC. | $173.96 | 2019-2021 | |
| Biogen, INC. | $130.16 | 2019-2022 | |
| Chiesi USA, INC. | $126.16 | 2019 | |
| Boston Scientific Corporation | $125.30 | 2020-2024 | Vercise |
| Neurocrine Biosciences, INC. | $107.30 | 2020-2024 | Ingrezza |
| Eisai INC. | $99.60 | 2025 | |
| Silk Road Medical, INC. | $97.30 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Jazz Pharmaceuticals INC. | $88.53 | 2019-2025 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruby Parveen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.